Skip to content 
Search

Latest Stories

Alzheimer's Society hails 'game-changing' results for lecanemab drug

Alzheimer's Society research shows that 900,000 people in the UK have a form of dementia.

Alzheimer's Society hails 'game-changing' results for lecanemab drug

Alzheimer's Society and professor Sir John Hardy on Wednesday (30) hailed 'game-changing' results for Alzheimer's drug lecanemab which can slow cognitive decline in patients.

Preliminary data from a trial of lecanemab was released in September and found it slowed cognitive decline by 27 per cent across an 18-month period.


The complete trial data, published in the New England Journal of Medicine, fleshes out those findings but also raises concern about the incidence of "adverse effects" including brain bleeds and swelling.

The results showed 17.3 per cent of patients administered the drug experienced brain bleeds, compared with nine per cent of those receiving a placebo. And 12.6 per cent of those taking the drug experienced brain swelling, compared with just 1.7 per cent of those in the placebo group.

Dr Richard Oakley, associate director of research at Alzheimer’s Society, said: “Today’s exciting results could be game-changing. They give us hope that in the future people with early Alzheimer’s disease could have more time with their loved ones. Our research over thirty years ago was pivotal in highlighting the importance of amyloid protein in Alzheimer’s disease, laying the foundations for billions of pounds of investment into many of the drugs like lecanemab being tested today, with 117 other drugs currently in trials.

“This isn’t the end of the journey for lecanemab – it's being explored in further trials to see how well it works over a longer period of time. The safety of drugs is crucial and lecanemab did have side effects, but they will be closely looked at when decisions are made about whether or not to approve lecanemab, to see if the benefits outweigh the risks."

In Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.

Dr Oakley added: “There is still a long way to go before we could see lecanemab available on the NHS, and we await clarity for how and when the approval process will take place in the UK, and whether regulators believe it is cost-effective. We mustn’t forget that lecanemab can only be given to people with early Alzheimer’s disease who have amyloid in their brain. This means people with other types of dementia, or in the later stages of Alzheimer’s disease, can’t benefit from this drug.

“We were excited to see a recommitment to the National Dementia Mission. This crucial doubling of dementia research funding must be delivered urgently, and must prioritise early diagnosis, through wider access to PET brain scans and research to get blood tests into the clinic, so people can access these drugs when they become available."

Professor Sir John Hardy, chair of molecular biology of neurological disease, UCL and Alzheimer’s Society funded researcher said: “Today marks a truly exciting day for dementia research. I’m incredibly proud of how far we’ve come since our Alzheimer’s Society funded research in 1989, which showed for the first time that a toxic protein called amyloid played a role in the cascade of brain changes leading to Alzheimer’s disease. This discovery would not have been possible without the selfless dedication of families affected by dementia who took part in this research. A drug like lecanemab becoming available on the NHS would be a massive triumph, but challenges remain around getting drugs to the right people at the right time – we need changes in our health system’s infrastructure to make sure we’re ready.”

By 2025, one million people will be living with dementia in the UK. Dementia deaths are rising year on year and 225,000 will develop dementia this year, one every three minutes.

More For You

Ping Pong restaurant chain shuts all UK branches

The chain had also gained a following for its themed brunches

iStock

Ping Pong restaurant chain shuts all UK branches after 20 years

Key points

  • Chinese dim sum restaurant Ping Pong has closed all its UK locations
  • The chain made the announcement via social media
  • Founded in 2005, the brand thanked customers and staff for their support
  • Loyal diners shared memories and disappointment in the comments

All branches are permanently closed

Chinese restaurant chain Ping Pong has permanently closed all its branches in the UK, the company confirmed in a social media announcement.

Founded in 2005 by restaurateur Kurt Zdesar, the dim sum chain had become popular for its stylish interiors, creative menus, and Asian-inspired cocktails. The company did not provide prior notice of the closure but said the decision marked the end of an “unforgettable” 20-year journey.

Keep ReadingShow less
New Covid strain

Experts have raised concerns about the immune-evasive nature of the Stratus strain

iStock

New Covid strain Stratus spreads in UK with unusual hoarse voice symptom

Key points

  • A new Covid strain known as Stratus is spreading across the UK
  • The variant is marked by a distinctive symptom: a hoarse or raspy voice
  • Sub-variants XFG and XFG.3 now account for 30% of cases in England
  • Experts say there is no evidence of more severe disease
  • Lower immunity levels may make more people vulnerable to infection

Covid variant Stratus on the rise in the UK

A new strain of Covid-19, known as Stratus, is spreading across the UK and drawing attention for its unusual symptom — a hoarse or raspy voice. According to data from the UK Health Security Agency (UKHSA), Stratus and its two sub-variants, XFG and XFG.3, are responsible for around 30 per cent of Covid cases in England.

Of the two, XFG.3 is currently the more dominant. The UKHSA confirmed that monitoring of all circulating Covid-19 variants is ongoing as part of regular surveillance.

Keep ReadingShow less
Human brain continues forming neurons

Neurogenesis, the process by which new neurons form in the brain

iStock

Human brain continues forming neurons well into old age, study finds

Key points

  • New neurons continue forming in the brain’s hippocampus into old age
  • Study confirms presence of neural progenitor cells in adults
  • DNA carbon dating and single-nucleus RNA sequencing were used
  • Research shows variation in neuron production between individuals
  • Findings could aid treatments for neurodegenerative and psychiatric disorders

Human brain shows ongoing neuron formation into older age

A new study has confirmed that the human brain continues to produce new nerve cells well into late adulthood, challenging previous assumptions about age-related decline in neurogenesis. The findings, published in the journal Science, provide fresh insight into how adaptable the brain remains over a lifetime.

Neurogenesis, the process by which new neurons form in the brain, is known to occur in the hippocampus — a region involved in memory. While previous research has suggested that this process continues throughout life, there has been limited concrete evidence of the presence of neural progenitor cells in the adult brain.

Keep ReadingShow less
Kent County Show 2025

Sophie, Duchess of Edinburgh, who grew up in Brenchley

Getty Images

Kent County Show opens with royal visit from Duchess of Edinburgh

Key points:

  • Day one of the Kent County Show begins at Detling Showground near Maidstone
  • The Duchess of Edinburgh visits the event for the first time in 16 years
  • Organisers expect up to 70,000 visitors over the weekend
  • Farming and rural life are at the centre of the three-day programme
  • Highlights include live camel racing, equine sports, livestock displays and more

Kent County Show opens with royal visit

The Kent County Show returned to Detling near Maidstone on Friday, marking the start of a major three-day celebration of farming, food, and rural living. The event opened with a special visit from the Duchess of Edinburgh, who is attending for the first time in 16 years.

Sophie, Duchess of Edinburgh, who grew up in Brenchley near Tunbridge Wells and serves as patron of the Association of Show and Agricultural Organisations (ASAO), met with farmers, equine exhibitors, and local businesses on her tour of the showground.

Keep ReadingShow less
Sri Aurobindo

Heehs’s biography is grounded in extensive archival research across France, England, India and Israel

AMG

Sri Aurobindo and the rise of the Asian century

Dinesh Sharma

My friend and colleague, the American historian Peter Heehs, who has lived in Pondicherry, India, for decades, recently published a compelling new biography, The Mother: A Life of Sri Aurobindo’s Collaborator (2025). Heehs previously authored The Lives of Sri Aurobindo (2008), which remains one of the most balanced and scholarly accounts of Aurobindo’s life.

According to Heehs, most previous biographies of the Mother were written for devotees and relied on secondary sources, often presenting her as a divine incarnation without critical engagement. “Such biographies are fine for those who see the Mother as a divine being,” Heehs said, “but they can be off-putting for readers who simply want to understand her life – as an artist, writer, spiritual teacher, and founder of the Ashram and Auroville.”

Keep ReadingShow less